(Q43890331)

27 November 2017

Different effects of acarbose and glibenclamide on proinsulin and insulin profiles in people with Type 2 diabetes (English)

1 reference

27 November 2017

1 reference

1 reference

1

Hanefeld M

1 reference

27 November 2017

2

Haffner SM

1 reference

27 November 2017

Menschikowski M

3

1 reference

27 November 2017

Koehler C

4

1 reference

27 November 2017

Temelkova-Kurktschiev T

5

1 reference

27 November 2017

Wildbrett J

6

1 reference

27 November 2017

Fischer S

7

1 reference

27 November 2017

1 March 2002

1 reference

Diabetes Research and Clinical Practice

27 November 2017

1 reference

27 November 2017

55

1 reference

27 November 2017

3

1 reference

27 November 2017

221-227

1 reference

Proinsulin processing in the regulated and the constitutive secretory pathway

27 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2801%2900347-3

7 January 2021

Direct measurement of plasma proinsulin in normal and diabetic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2801%2900347-3

7 January 2021

Circulating proinsulin-like molecules

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2801%2900347-3

7 January 2021

Disproportionately elevated proinsulin in Pima Indians with noninsulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2801%2900347-3

7 January 2021

Structural domains and molecular lifestyles of insulin and its precursors in the pancreatic beta cell

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2801%2900347-3

7 January 2021

The relationships of concentrations of insulin, intact proinsulin and 32-33 split proinsulin with cardiovascular risk factors in type 2 (non-insulin-dependent) diabetic subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2801%2900347-3

7 January 2021

LDL particle size in relation to insulin, proinsulin, and insulin sensitivity. The Insulin Resistance Atherosclerosis Study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2801%2900347-3

7 January 2021

The relationship of concentrations of insulin and proinsulin-like molecules with coronary heart disease prevalence and incidence. A study of two ethnic groups.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2801%2900347-3

7 January 2021

Treatment of NIDDM with insulin agonists or substitutes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2801%2900347-3

7 January 2021

Effect of sulfonylurea withdrawal on proinsulin levels, B cell function, and glucose disposal in subjects with noninsulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2801%2900347-3

7 January 2021

The long-term effects of chlorpropamide on insulin, C-peptide, and proinsulin secretion.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2801%2900347-3

7 January 2021

Effect of chronic sulfonylurea therapy on plasma insulin and proinsulin levels

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2801%2900347-3

7 January 2021

Effect of metformin on intact proinsulin and des 31,32 proinsulin concentrations in subjects with non-insulin-dependent (type 2) diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2801%2900347-3

7 January 2021

Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose-comparison study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2801%2900347-3

7 January 2021

Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2801%2900347-3

7 January 2021

Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. The Essen Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2801%2900347-3

7 January 2021

Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2801%2900347-3

7 January 2021

Increased intimal-medial thickness in newly detected type 2 diabetes: risk factors.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2801%2900347-3

7 January 2021

Postprandial plasma glucose is an independent risk factor for increased carotid intima-media thickness in non-diabetic individuals.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2801%2900347-3

7 January 2021

Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2801%2900347-3

7 January 2021

Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2801%2900347-3

7 January 2021

Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2801%2900347-3

7 January 2021

Glibenclamide, but not acarbose, increases leptin concentrations parallel to changes in insulin in subjects with NIDDM

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2801%2900347-3

7 January 2021

The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2801%2900347-3

7 January 2021

The effect of acarbose on insulin sensitivity and proinsulin in overweight subjects with impaired glucose tolerance.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2801%2900347-3

7 January 2021

Acarbose controls postprandial hyperproinsulinemia in non-insulin dependent diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2801%2900347-3

7 January 2021

Will acarbose improve the metabolic abnormalities of insulin-resistant type 2 diabetes mellitus?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2801%2900347-3

7 January 2021

Effect of acarbose on postprandial lipid metabolism in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2801%2900347-3

7 January 2021

Effect of sulphonylurea therapy on plasma insulin, intact and 32/33 split proinsulin in subjects with type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2801%2900347-3

7 January 2021

Proinsulin and insulin concentrations in relation to carotid wall thickness: Insulin Resistance Atherosclerosis Study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2801%2900347-3

7 January 2021

High proinsulin concentration precedes acute myocardial infarction in a nondiabetic population

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2801%2900347-3

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2801%2900347-3

7 January 2021

Safety and efficacy of acarbose in the treatment of Type 2 diabetes: data from a 5-year surveillance study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2801%2900347-3

7 January 2021

The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insuli

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2801%2900347-3

7 January 2021

10.1016/S0168-8227(01)00347-3

Identifiers

DOI

1 reference

27 November 2017

1 reference